20 Nov 2017 | 6:10 PM
 

Cadila Healthcare Ltd. Share Price Live (BSE)
0

BSE Code: 532321 | NSE Symbol: CADILAHC
446.30
-0.05
(-0.01 %)
20 Nov 2017 | 03:55 PM
Change company
  • Open (Rs)
    450.55
  • Prev. close (Rs.)
    446.35
  • High (Rs.)
    453.70
  • Low (Rs.)
    443.35
  • 52W H (Rs.)
    558.00
  • 52W L (Rs.)
    329.95
  • Volume
    76325
  • MCap (Rs in Cr.)
    45,689.66

Stock Market News

Cadila Healthcare Ltd. Stock News

Company Name
From Date
To Date
  Cadila Healthcare Ltd. | 20 Nov 2017 | 12:39:00
Zydus Cadila announced that the WHO INN committee has granted the name Desidustat to its phase II anemia candidate ZYAN1...
  Cadila Healthcare Ltd. | 20 Nov 2017 | 10:55:00
Zydus Cadila has received final approval from the US health regulator to market Ethacrynate sodium for injection used to reduce swelling caused by various diseases...
  Cadila Healthcare Ltd. | 20 Nov 2017 | 09:22:00
Zydus Cadila has said that it has received the final approval from the US Food & Drug Administration (USFDA) to market Ethacrynate Sodium for Injection USP 50 mg/vial...
  Cadila Healthcare Ltd. | 14 Nov 2017 | 14:08:00
The company reported standalone net profit of Rs 449.80 crore for the quarter ended September 30 2017 as compared to Rs 109.00 crore in the same period last year registering a year-on-year growth of 312.66 per cent...
  Cadila Healthcare Ltd. | 10 Nov 2017 | 15:00:00
Cadila Healthcare has said that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) has granted marketing approval to commercialize Lipaglyn™ (Saroglitazar Magnesium) in Mexico for the treatment of D...
  Cadila Healthcare Ltd. | 02 Nov 2017 | 13:01:00
Nesher Pharmaceuticals a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the US Food and Drug Administration to market Dextroamphetamine Sulfate and Amphetamine Sulfate tablets...